Success Metrics

Completion Rate

0%(0/1)

Active Trials

2(67%)

Terminated

1(33%)

Phase Distribution

Ph phase_3

33%

Ph phase_1

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Terminated(1)

Detailed Status

Active, not recruiting2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (66.7%)

Phase 31 (33.3%)

Trials by Status

terminated133%

active_not_recruiting267%

Recent Activity

2 active trials

Showing 3 of 3

active_not_recruitingphase_3

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

NCT06246513

active_not_recruitingphase_1

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

NCT05876780

terminatedphase_1

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

NCT03652259

Clinical Trials (3)

Showing 3 of 3 trials

NCT06246513Phase 3

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

Active Not Recruiting

NCT05876780Phase 1

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

Active Not Recruiting

NCT03652259Phase 1

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

Terminated

All 3 trials loaded

Drug Details

Intervention Type: GENETIC
Total Trials: 3